Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
ENTITY
Shanghai Henlius Biotech (2696 HK)
Watchlist
109
Analysis
Health Care
•
China
Shanghai Henlius Biotech, Inc develops and produces drugs. The Company develops and produces monoclonal antibody biosimilar drugs, bio betters, novel monoclonal antibodys, and other drugs. Shanghai Henlius Biotech throughout China.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
Zhejiang Orient Gene Biotech C
•
03 Dec 2023 09:29
China Healthcare Weekly (Dec.1) - Medical Device VBP, Biotech to Breakeven Soon, Orient Gene Biotech
VBP result for intraocular lens/sports medicine consumables is better than expected.There’s a chance to see Chinese Biotech turn loss into profits...
Xinyao (Criss) Wang
Follow
443 Views
Share
bullish
•
Thematic (Sector/Industry)
•
05 Nov 2023 09:50
China Healthcare Weekly (Nov.3)-Share Price Correction,Valuable Shortcut,Globalization Vs Innovation
Success of globalization ultimately relies on strong innovative capabilities. Here's how to distinguish valuable shortcuts - Me-Too strategy....
Xinyao (Criss) Wang
Follow
332 Views
Share
bearish
•
3D Medicines
•
22 Jun 2023 08:55
3D Medicines (1244.HK) - The Bubble Will Eventually Burst
3DMed's current stock price is clearly unreasonable. Its financial situation and the prospects of core product indicate that its survival issues...
Xinyao (Criss) Wang
Follow
410 Views
Share
bullish
•
Thematic (Sector/Industry)
•
18 Apr 2023 08:55
China Biotech – The Commercialization Performance and The Outlook
In the context of the fading dividend of medical system reform and the lack of next big variety, the previous wave of innovative drug boom is hard...
Xinyao (Criss) Wang
Follow
279 Views
Share
bullish
•
Thematic (Sector/Industry)
•
02 Jan 2023 08:55
China Healthcare Weekly (Jan.1) - NRDL Negotiation Turnaround, Pullback of TCM, Biotech Sales System
This year's NRDL negotiation could be “a landmark event” for innovative drug industry.Pullback of TCM may really begin from 23Q2.We analyzed...
Xinyao (Criss) Wang
Follow
436 Views
Share
First
Previous
7
8
9
10
11
12
13
Next
Last
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.34.2
x